PAGE 2 IMS HEALTH REAL-WORLD EVIDENCE SOLUTIONS
INSIGHTS HOW IS ONCOLOGY TREATMENT EVOLVING?
ACCESSPOINT • VOLUME 6 • ISSUE 12 PAGE 3
0
20
40
60
80
100
Upcoming Development by Tumor TypeLaunches by Year0
5
10
15
20
25
30
20172016 2018 2019 2020 >2020
The Current Oncology Pipeline:Development & Launch
Exceptional launch activity increases options for patients but requires a greater understanding of treatment pathways and patient segments for payers and clinicians. The sheer volume of potential new products drives a need to reassess the way information about these expanded options is conveyed to stakeholders.
These figures are estimates based on phase III completion dates. The actual number of launches will depend on successful trial completion and FDA approval. Products in phase II that could successfully move through launch are not included.
Intense R&D activity reflects tremendous market growth and an increased understanding of oncology. Of the 100+ molecules in phase III development, 68% are targeted agents, illustrating how oncology will become even more specialized.
BreastCancer
Non-Small Cell Lung Cancer
80%
10%
10%
OvarianCancer
Acute Myeloid Leukemia
GastricCancer
8%
46%
23%
23%
66%
17%
17%
66%
17%
17%
80%
20%
50%
50%
HepatocellularCarcinoma
Melanoma
38%
49%
7%3%3%
75%
25%
68%
26%
100%
ColorectalCancer
61%
13%
13%
13%
Renal Cell Cancer
Non-HodgkinLymphoma
Others
4
66
5 4
19 19 13 8
4 29
6%
57%
11%
26%
2%2% 2%
11
3312%
73%3%12%
58
53%
34%
13% 54%42% 4%
61%35% 4%
47
24
23
73%
18%
9%
70%20%
10%
47% 53%
83%17%58%
14%
14%
14%
41%
3%
56% 39
10
7 6
2986%7%7%
20%
15
Launch activity over the next 4 years promises a range of new options across solid and hematological malignancies
Note: Represents the top 10 tumors by number of launches from 2016-2020
Number of LaunchesAcute Myeloid
Leukemia
47%33% 15
GastricCancer
20%
Hepato-cellular
Carcinoma
MelanomaBreastCancer
80%
10%
10% 10
OvarianCancer
ColorectalCancer
100% 8
Chronic Lymphocytic
Leukemia
100% 10
Non-HodgkinLymphoma
Non-Small Cell Lung
Cancer
Source all data: IMS R&D Focus; www.clinicaltrials.gov
Vaccine
Targeted
Oncolytic Virus
Immuno-oncology
Others
Chemotherapy
Activity Breakdown
original data graphs, always copy/paste to edit
scale 80% and additional 80% smaller to create shading
Unprecedented launches signal new needs for stakeholder engagement
68%
2%
7%
18%
VaccineImmuno-oncologyTargeted Chemotherapy Oncolytic Virus Other
n=101
Saurabh Kumar, MD, MBA – Senior Manager, Global Delivery Center, IMS Health, [email protected] Divya Dhingra, MSC – Associate Consultant, IMS Health, [email protected]
2016 2018 2019 2020 >20202017
3% 2%
Total Clinical Activity
18%